1 / 19

mTOR: a new pathway to target in oncology

mTOR: a new pathway to target in oncology. Madlaina Breuleux, PhD Novartis Phrma AG Basel, Switzerland. The mTOR pathway and cancer. mTOR ( m ammalian “ T arget O f R apamycin”):. A high molecular weight serine-threonine kinase Senses and responds to cellular nutrient and energy levels

meyermark
Download Presentation

mTOR: a new pathway to target in oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. mTOR: a new pathwayto target in oncology MadlainaBreuleux,PhD NovartisPhrmaAG Basel,Switzerland

  2. The mTOR pathway and cancer mTOR (mammalian “Target Of Rapamycin”): • A high molecular weight serine-threonine kinase • Senses and responds to cellular nutrient and energy levels • Influences protein translation regulating G1 progression, S-phase entry, and ultimately cell growth and proliferation • Functions downstream of the PI3 kinase / AKT pathway, which is often deregulated in human cancer • mTOR pathway deregulation causes loss of growth control in cancer

  3. mTOR: A central controller of tumor cell growth

  4. mTOR: A controller of angiogenic processes

  5. RAD001 (Everolimus): An oral mTOR pathway inhibitor • Broad antiproliferative and antitumor properties • Inhibits the mTOR pathway • Sensor of physiological signals • “Downstream“ of PI3K / AKT pathway • RAD001 activity associated with overactivation of the PTEN / PI3K / AKT pathway • Inhibits tumor cell growth • Delays G1/S phase progression • Sensitises tumor cells to targeted and chemotherapeutic agents • Anti-angiogenic properties • Direct and indirect activity • Phase IB/II clinical trials in oncology Model of RAD001 binding to intracellular receptor (FKBP-12) to form complex inhibiting mTOR pathway

  6. p-AKT levels correlate with RAD001 sensitivity

  7. RAD001: Broad in vivo antitumor activity

  8. mTOR inhibition decreases angiogenesis • mTOR regulates HIF-1α and HIF-2α expression (transcription factors mediating hypoxia-induced gene expression) • HIF-1α/2α are normally degraded by VHL protein • HIF-1 and HIF-2 condition the tumor to adapt to growth under hypoxic conditions and promote angiogenesis and metastasis HIF = hypoxia-inducible factor; VHL = von Hippel-Lindau protein.

  9. Evidence of antiangiogenic activity • Tumor xenograft–bearing mice: single 5 mg/kg oral dose • RAD001 plasma levels never exceed the in vitro IC50 for HCT116 (colon) or KB-31 (epidermoid) tumor cells • However, both HCT116 and KB-31 xenografts are sensitive to RAD001 in vivo at this dose • RAD001 levels exceed the in vitro IC50 for VEGF- or FGF-stimulated human umbilical vein endothelial cultures (HUVECs) • RAD001 inhibits tumor cell VEGF production in vitro and decreases tumor and plasma VEGF levels in animal models • RAD001 selectively inhibits VEGF-dependent angiogenic response in vivo, and reduces microvessel density in tumors derived from sensitive or resistant cell lines • These data suggest an antiangiogenic effect against tumors

  10. RAD001 reduces microvessel density (B16/BL6) Vehicle Controls RAD001 Significant reduction in microvessel density following RAD001 treatment in primary tumor and cranial lymphnode metastases (shown)

  11. RAD001: Combination potential Although RAD001 has antiproliferative activity as a monotherapy, its potential may be better realized in combination with other therapeutic agents • Chemotherapeutics • DNA-damaging agents (i.e. cisplatin, temozolomide) • Topoisomerase inhibitors (i.e. doxorubicin) • MT active agents (i.e. Taxol) • Targeted therapeutics • ErbB inhibitors (i.e. AEE788; trastuzumab) • Estrogen antagonists - aromatase inhibitors (i.e. letrozole) • BCR-ABL, Kit inhibitors (i.e. imatinib) • VEGFR inhibitors (i.e. PTK787) • IGF-1R inhibitors (i.e. AEW541) • Radiotherapy

  12. Combinations with cisplatin(in RAD001-sensitive H596 NSCLC xenografts) Tumor Volumes Body Weights Combinations of RAD001 and low-dose cisplatin elicit a more potent antitumor effect than either agent alone (also in model derived from resistant line) * P < 0.05 versus controls by the Dunnett test.

  13. Cisplatin combinations: Potentiate cell death(A549 cells: cell death with sub-optimal cisplatin concentrations) *Significant fold induction with P < 0.05, t-tests; two-way ANOVA indicates highlysignificant interaction between RAD001 and cisplatin P < 0.001.

  14. Cell death is dependent on p53 status * Significant fold induction with P < 0.05, t-tests.

  15. The p53/p21 response • DNA damage (i.e cisplatin treatment) activates p53. • In the presence of extensive DNA damage, p53 initiates a cell death program. • In the presence of sub-optimal DNA damage, p53 induces p21 expression, a cell cycle inhibitor, allows DNA repair (and cell survival). • RAD001 inhibits p21 expression forcing tumor cell death even at suboptimal cisplatin concentrations (non-lethal DNA damage) Beuvink et al. Cell. 2005;120:747-759.

  16. Rationale for combination with letrozole • Akt activation predicts a worse outcome for breast cancer patients treated with endocrine therapy. • Activated Akt mediates resistance to antiestrogen therapy (related to HER2 overexpression). • mTOR inhibition restores responses to tamoxifen in breast cancer models with high levels of Akt activity. • Synergistic in vitro and in vivo effects have been seen with combined antiestrogen therapy and mTOR inhibition.

  17. Inhibition of estrogen-induced proliferation(aromatase-expressing MCF7 cells) Highly significant interactions ( p < 0.001; two-way ANOVA) Synergistic effects (isobologram analysis) Also in aromatase-expressing T47D cells

  18. Potential RADIANT Trials TUNEL YOPRO Decreased cell viability as compared to single agents (YOPRO:  p < 0.01; two-way ANOVA). Defined as apoptosis (TUNEL:  p < 0.05; Friedman Test). Also in aromatase-expressing T47D cells

  19. Summary • mTOR acts as a central regulator of tumor cell growth and survival, and activation of the PI3K/AKT pathway may predict tumor response to mTOR inhibition. • RAD001 exhibits a broad antitumor activity, and inhibits elements of the angiogenic process. • Combination therapy targeting mTOR and other targets/processes deregulated in human cancer may provide enhanced anticancer activity. Targeting deregulated pathways has been a successful clinical strategy in cancer.

More Related